Tilray Stock Buy or Sell? TLRY Stocks Forecast

Market Capitalization: 1 612 568 000 $
EBITDA: -68 897 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.071
Trailing PE: -
Forward PE: 1000
Shares Outstanding: 617842000

Tilray Stock Buy or Sell? TLRY Stocks Analytic Forecasts

March 24, 2023 (05:19)

Tilray, Inc. (TLRY) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the TLRY stock market. Experts share their opinions on what to expect from the Tilray, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Tilray stocks.

Tilray, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy TLRY Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of John Engle and is titled

“Tilray: Down 89%, But Still Far From A Bargain”

is published on March 20 (2023) and has 0 likes. The review predicts Bearish market trend.

It summarize the following theses:

  • Cannabis stocks remain highly exposed to the Canadian market; Tilray, long Canada’s top producer, is especially so.
  • Tilray, along with many of its peers, are working to shift focus from Canada to more lucrative international markets.
  • Tilray has established itself on three continents, and is now Germany’s biggest cannabis player.
  • Efforts to penetrate the prized US market, however, have proven slow and challenging thus far.
  • While Tilray’s stock has fallen 89% from its all-time high, it remains far from a bargain.

The author starts his analytic review with the following:

You’re operating your cannabis business in a bad market; or

The opinion of the author can be considered quite authoritative.
The number of 6618 followers confirms this.
John Engle is the contributor of experts community
since 2017 and has 330 works published.

One more noteworthy article is written by Blake Downer under the title

“Tilray Is Still Struggling To Find Its Footing”

on March 8 (2023) and has 0 likes. The expert reflects Bearish trend of the market.

Нis theses make you think about whether to add TLRY stocks to your investment portfolio or not, and helps to work out your own Tilray stock selling strategies:

  • Tilray has been unable to find operational profits.
  • Revenue has been declining for the last 6 quarters.
  • Costs have been climbing as margins have failed to improve.

Blake Downer starts analysis with such words:

Thesis The ongoing price war in the Canadian cannabis sector has seen overproduction lead to an extremely competitive ecosystem where growers are regularly destroying expired flower. Tilray Brands, Inc. (NASDAQ:TLRY) has been unable to improve its negative operating margins and has slowly declining quarterly revenues. Though it has maintained a healthy war chest of available cash, it has done so through dilution.

The author declares an interesting position, and the number of his followers is 173 and it grows, but not that weighty compared to other authors.
Blake Downer has 9 works published.
The contributor of experts community since 2023. Has published at least 9 articles.

Another analysis presented by Alan Brochstein, CFA came out on February 15 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for TLRY stocks. It sounds like

“Looking For The Cheapest Cannabis Stocks (Transcript)”

Article has got 5 likes at the moment and forecasting trend of the market.

Summarizing the information presented in the review concerning the Tilray, Inc., the expert says the following:

  • Cannabis stocks are really cheap, but Alan Brochstein is worried about 3 things.
  • Thoughts on Cresco/Columbia Care deal.
  • Sector debt and optimal cannabis investing metrics. Canadian and US operators.
  • Concerns around MSOS; limitations of ETFs.

And here, what comes first:

This author is very popular among the auditory. He has 70916 followers.

Alan Brochstein, CFA is the contributor of experts community since 2007 and has at least 672 analytic reviews published.

The Share Price of Tilray, Inc. (TLRY) for now

What analysts predict: $4.39
52-week high/low: $9.08 / $2.28

50/200 Day Moving Average: $2.911 / $3.356

The average stock price over the previous 50/200 days. For Tilray stocks, the 50-day moving average is the resistance level for now. For TLRY stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for TLRY stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

UnitedHealth: Buy – May Not Be A SWAN, But It’s A SUN For Me

Buy or Sell UNH shares? UnitedHealth: Buy – May Not Be A SWAN, But It’s A SUN For Me
March 16, 2023
UnitedHealth has become a leader in creating a profitable business model to help bend the healthcare cost curve, and its business model is being adapted by its peers.

Merck: All Eyes On Key Clinical Catalyst In March

Buy or Sell MRK shares? Merck: All Eyes On Key Clinical Catalyst In March
February 28, 2023
Merck is an American biopharma powerhouse that has generated consistent compounding growth, increasing its top line and EPS.

Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

Buy or Sell AADI shares? Aadi Bioscience: Commercial Stage With Large Market In Label Expansion
March 6, 2023
AADI is a commercial stage company with a potential label expansion ahead.